rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Intensity Therapeutics, Inc.

INTS · Nasdaq

Health CareBiotechnologyNot moving yet

INTS stood above a rising 150-day average in 3 of the last 52 weekly readings, and has been out of that trend for the last 36 weeks. It is 27.2% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 36
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
17 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 3 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders17+4 on the quarter
New · exited5 · 1
Reported value$4.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Kingsbury Capital Investment Advisors LLCadded · filed 25 Aug 2026496,493$2.0M+458,439+1204.7%
KMT WEALTH MANAGEMENT, LLCnew · filed 5 Aug 2026496,493$2.0M+496,493
Rothschild Wealth LLCadded · filed 11 Aug 202626,723$110K+3,429+14.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202626,569$109K+9,728+57.8%
SAPIENT CAPITAL LLCunchanged · filed 9 Jul 202626,006$107K00.0%
NANO CAP NEW MILLENNIUM GROWTH FUND L Punchanged · filed 14 Aug 202625,000$103K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202622,787$93K-3,232−12.4%
Mesirow Financial Investment Management, Inc.unchanged · filed 22 Jul 202614,118$58K00.0%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 20269,121$37K00.0%
Tower Research Capital LLC (TRC)added · filed 11 Aug 20261,984$8,134+1,917+2861.2%
30 Jun 2023 – 30 Jun 2026
31833Jun 23Mar 24Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Daniel Donovan Company insiderDirector · last 16 Jul 20260 · 0
Emer Leahy Company insiderDirector · last 16 Jul 20260 · 0
John M. Wesolowski Company insiderPrincipal Accounting Officer · last 16 Jul 20260 · 0
Joseph Talamo Company insiderChief Financial Officer · last 16 Jul 20260 · 0
Lewis H. Bender Company insiderPresident and CEO · last 16 Jul 20260 · 0
Mark A. Goldberg Company insiderDirector · last 16 Jul 20260 · 0
Thomas I. H. Dubin Company insiderDirector · last 16 Jul 20260 · 0

Same industry

MRNA ModernaLeading+154%
IOVA Iovance BiotherapeuticsLeading+133%
ABCL AbCellera BiologicsLeading+61%
ENTX Entera BioLeading+49%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+46%
HELP Helus PharmaLeading+37%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-100%
Share count trendFY 2025 · to 26 Mar 20260.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$11.9M

Analyst forecasts

No analyst forecasts yet.